Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2026. Recent Business Highlights: Pivotal results from the FULCRUM-VT trial presented in late-breaking session at Heart Rhythm Society 2026 – the first large-scale, rigorously executed pivotal trial in patients with bot.